|Committee Member||Research Grant||Speakers’ Bureau/Honoraria||Stock Ownership||Board of Directors||Consultant/Advisory Member|
|Dr. Elliott M. Antman⁎||Dr. Antman is a senior investigator in the TIMI Study Group, which received grants from the following sources:||None||None|
|Dr. Paul W. Armstrong‡||None||None|
|Dr. Eric R. Bates||None||None||None|
|Dr. Lee A. Green||None||None||None||None||None|
|Dr. Lakshmi K. Halasyamani||None||None||None||None||None|
|Ms. Mary Hand||None||None||None||None||None|
|Dr. Judith S. Hochman§||None||None||None|
|Dr. Harlan M. Krumholz||None||None||None|
|Dr. Gervasio A. Lamas§||None||None|
|Dr. Charles J. Mullany||None||None||None||None||None|
|Dr. David L. Pearle||None||None||None||None|
|Dr. Michael A. Sloan||None||None||None|
|Dr. Sidney C. Smith, Jr.‖||None||None||None|
This table represents the actual or potential relationships with industry that were reported. This table was updated in conjunction with all conference calls of the writing committee. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10 000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.
↵⁎ Recused from voting on Section 8: Anticoagulants as Ancillary Therapy to Reperfusion Therapy and Section 10: Anticoagulants.
↵† Indicates a relationship valued at $10 000 or more.
↵‡ Recused from voting on Section 5: Facilitated PCI.
↵§ Recused from voting on Section 7: PCI After Fibrinolysis or for Patients Not Undergoing Primary Reperfusion.
↵‖ Recused from voting on Section 13: Antiplatelet Therapy.